My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 113

    1.

    GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

    Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ.

    Diabetes. 2009 Apr;58(4):975-83. Epub 2009 Jan 16.PMID: 19151200 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice.

    Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ.

    Diabetes. 2009 Sep;58(9):2148-61. Epub 2009 Jun 9.PMID: 19509017 [PubMed - indexed for MEDLINE]Related articles

    3.

    Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.

    Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M.

    Circulation. 2008 May 6;117(18):2340-50. Epub 2008 Apr 21. Erratum in: Circulation. 2008 Jul 22;118(4):e81. PMID: 18427132 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.

    Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J; NN2211-1499 Study Group.

    Exp Clin Endocrinol Diabetes. 2006 Sep;114(8):417-23.PMID: 17039422 [PubMed - indexed for MEDLINE]Related articles

    5.

    Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo.

    Baggio LL, Kim JG, Drucker DJ.

    Diabetes. 2004 Dec;53 Suppl 3:S205-14.PMID: 15561912 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Liraglutide: a new treatment for type 2 diabetes.

    Vilsboll T.

    Drugs Today (Barc). 2009 Feb;45(2):101-13. Review.PMID: 19343230 [PubMed - indexed for MEDLINE]Related articles

    7.

    Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

    Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group.

    Diabetes Care. 2004 Jun;27(6):1335-42.PMID: 15161785 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.

    Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jetté L, Benquet C, Drucker DJ.

    Diabetes. 2003 Mar;52(3):751-9.PMID: 12606517 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

    Harder H, Nielsen L, Tu DT, Astrup A.

    Diabetes Care. 2004 Aug;27(8):1915-21.PMID: 15277417 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.

    Baggio LL, Huang Q, Cao X, Drucker DJ.

    Gastroenterology. 2008 Apr;134(4):1137-47. Epub 2008 Jan 11.PMID: 18313669 [PubMed - indexed for MEDLINE]Related articles

    11.

    Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

    Baggio LL, Huang Q, Brown TJ, Drucker DJ.

    Gastroenterology. 2004 Aug;127(2):546-58.PMID: 15300587 [PubMed - indexed for MEDLINE]Related articles

    12.

    One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

    Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O.

    Diabetes. 2004 May;53(5):1187-94.PMID: 15111485 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.

    Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ.

    J Biol Chem. 2003 Jan 3;278(1):471-8. Epub 2002 Oct 29.PMID: 12409292 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.

    Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group.

    Diabet Med. 2005 Aug;22(8):1016-23.PMID: 16026367 [PubMed - indexed for MEDLINE]Related articles

    15.

    Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.

    Monami M, Marchionni N, Mannucci E.

    Eur J Endocrinol. 2009 Jun;160(6):909-17. Epub 2009 Mar 24.PMID: 19318378 [PubMed - indexed for MEDLINE]Related articles

    16.

    The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.

    Maida A, Lovshin JA, Baggio LL, Drucker DJ.

    Endocrinology. 2008 Nov;149(11):5670-8. Epub 2008 Jul 31.PMID: 18669601 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.

    Seino Y, Rasmussen MF, Zdravkovic M, Kaku K.

    Diabetes Res Clin Pract. 2008 Aug;81(2):161-8. Epub 2008 May 20.PMID: 18495285 [PubMed - indexed for MEDLINE]Related articles

    18.

    GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.

    Sturis J, Gotfredsen CF, Rømer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, Carr RD, Knudsen LB.

    Br J Pharmacol. 2003 Sep;140(1):123-32. Epub 2003 Jul 29.PMID: 12967942 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.

    Chen D, Liao J, Li N, Zhou C, Liu Q, Wang G, Zhang R, Zhang S, Lin L, Chen K, Xie X, Nan F, Young AA, Wang MW.

    Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):943-8. Epub 2007 Jan 9.PMID: 17213311 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice.

    Thorkildsen C, Neve S, Larsen BD, Meier E, Petersen JS.

    J Pharmacol Exp Ther. 2003 Nov;307(2):490-6. Epub 2003 Sep 15.PMID: 12975499 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity